Vas Narasimhan
11 statements across 1 episodes · 7 bullish · 3 bearish · 1 people on the record · first statement Jan 17, 2019 by Vas Narasimhan · said 4 times in 1 episodes since 2019 · across every show →
On the record as a speaker too: Vas Narasimhan's record, appearances and statements → this page counts the times other people say the name.
Mentions by year
brought up most by Koki Hirasaki (4)
tap a year for its mentions
2019 4 mentions in 1 episode
Everything said about Vas Narasimhan, oldest first
Jan 17, 2019 negative
Novartis spent years just cleaning healthcare data before running AI algorithms
“We've had to spend most of the time just cleaning the data sets before you can even run the algorithm. That's just taken us years just to clean the data sets. And I think people underestimate how little clean data there is out there and how hard it is”
Jan 17, 2019 bullish
AI outperforms internal human analysts at forecasting Novartis product sales
“The other area, interestingly, in the financial area as well, we find that AI does a great job predicting our free cashflow, predicting a lot of our sales for key products, and it does better than our internal people because it doesn't have the biases and the …”
Jan 17, 2019 bullish
Narasimhan: CAR-T therapy development will shift to an iterative model
“I think in the specific example of car T I do think that's, what's going to happen because you have such a complex manufacturing that you're going to have the first generation, let's say of a CD-nineteen card, which is a cart that targets B cell cancers. And y…”
Jan 17, 2019 bearish
Jan 17, 2019 bullish
Narasimhan: AAV vectors enable reusable platform delivery in gene therapy
“When you think about AAV vectors, these are ways to deliver these gene therapies into the body. Once you solve it, the process, let's say for one of these vectors, you can apply it to multiple different diseases and not have to Recreate everything again. That'…”
Jan 17, 2019 neutral
Pharma clinical trial success rates have stayed flat at 5 percent
“And actually, when you look at attrition rates in our industry, really the chances of success that we have, they haven't moved in the last 15 years. Still, when we bring a medicine into human beings, on average, only one out of 20 works.”
Jan 17, 2019 bearish
AI in digital health currently offers very little actual impact
“Well, I have to first say, I completely agree about the hype cycle here. I mean, as we've gotten quite scaled and working on digital health and data science, we've learned that there's a lot of talk and very little in terms of actual delivery of impact.”
Jan 17, 2019 positive
Viable animal-to-human organ xenotransplantation will arrive within 10 to 20 years
“I think a couple of things will likely come. I think xenotransplantation, I mean, which has been in and out and worked on. And what's interesting is every one of these comes up and down. So, you know, gene therapies, cell therapies popped up in the nineties, k…”
Jan 17, 2019 positive
Jan 17, 2019 positive
Narasimhan: RNA therapies are the only way to drug LP(a)
“And so the only way to really target it turns out to be using RNA based therapies. These RNA based therapies are able to block the production of the gene translation of the gene into the protein and then actually reduce the LP little a in the blood.”